What Vaxine does

Vaxine Pty Ltd is an Adelaide, South Australia-based biotechnology company founded in 2002 (relocating to its current headquarters in 2004) that develops vaccines and immunotherapies for infectious diseases, neurodegenerative conditions, cancer, and allergy. The company's technical foundation is its patented Advax™ adjuvant platform, a delta inulin polysaccharide technology that enhances vaccine immunogenicity, combined with AI-driven computational methods for rapid vaccine and drug design. Vaxine's portfolio spans roughly 15 vaccine programs, including the Covax-19/SpikoGen® recombinant spike protein COVID-19 vaccine (which received marketing authorization in Iran in October 2021 and pediatric approval in May 2023, with 8 million doses distributed in the Middle East via partner Cinnagen Corporation), universal and seasonal influenza candidates, hepatitis B, Japanese encephalitis, Ebola, malaria, tuberculosis, anthrax, HIV, RSV, Zika, typhoid, shigella, and opioid addiction vaccines, alongside an Alzheimer's disease vaccine that entered human trials in June 2024 and a TLR-agonist cancer immunotherapy in clinical development.

Vaxine operates a hybrid revenue model anchored by approximately USD $50 million in cumulative non-dilutive research grants from the US National Institutes of Health and Australian government bodies (awarded principally to founder Professor Nikolai Petrovsky over 20 years), supplemented by one-time vaccine product sales and licensing/royalty income from partners such as Cinnagen Corporation (Middle East distribution), Matrivax Inc (typhoid co-development), Protein Sciences (Zika co-development), and the Institute for Molecular Medicine (Alzheimer's collaboration). The company is founder-led, privately held, headquartered within Flinders Medical Centre, and reports a headcount of 11-50 employees. Pricing of vaccine products is not publicly disclosed as distribution occurs through government health systems and regulatory-approved channels.

Name

Vaxine

Legal name

Vaxine Pty Ltd

Website

https://vaxine.net

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Vaxine is an Adelaide-based Australian biotechnology company developing vaccines and immunotherapies using its patented Advax™ delta inulin adjuvant platform and AI-driven design. Its portfolio spans COVID-19, influenza, Alzheimer's, cancer, and allergy, distributed via government channels and partners like Cinnagen Corporation.

Ownership category

akta.pro rank

Product category

Vaccines and Biologics Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Vaccine Adjuvants & Formulation Systems (HLAIAEAI), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Vaccine Combination Products (Multivalent/Co-formulated) (HLAIAEAO)

Keywords

• Vaccine development
• Adjuvant technology
• Immunotherapy products
• Biologics manufacturing
• Influenza vaccines

Headquarters

HQ city

Adelaide

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Vaccine Product Sales: Revenue from sale of approved vaccines including COVID-19 vaccine (SpikoGen/Covax-19) distributed in the Middle East through partner Cinnagen Corporation. 8 million doses delivered to date.
2. Technology Licensing: Licensing of Advax adjuvant platform and vaccine technologies to partner companies for development and commercialization.
3. Government Research Grants: Competitive research funding from US National Institutes of Health and Australian government funding bodies. Professor Petrovsky has been awarded over $50 million in vaccine grants.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Vaxine develops, manufactures and licenses vaccines and immunotherapies built on its proprietary Advax™ polysaccharide adjuvant platform, combined with an AI-driven vaccine design capability (SYNVOLUX). The company sells a TGA-approved Advax-adjuvanted COVID-19 vaccine, supplies Advax-formulated pandemic influenza vaccines for emergency response, and is advancing an Advax-adjuvanted Alzheimer's disease vaccine candidate (AV-1980R) through clinical development. Its Adjuvant IP is also licensed to other vaccine developers globally.

Product overview

Vaxine is an Australian biotechnology company that has developed an extensive portfolio of vaccines and immunotherapies over the last 20 years. The company's core technology is its Advax™ adjuvant platform, a patented delta inulin polysaccharide adjuvant that enhances vaccine immune responses. This platform is combined with AI-driven rapid drug design capabilities. The portfolio includes: COVID-19 vaccine (Covax-19/SpikoGen®) which received marketing authorization in the Middle East in 2021; Alzheimer's Disease vaccine entering human trials in 2024; Cancer Immunotherapy using toll-like receptor agonists; Allergy Immunotherapy; and various infectious disease vaccines including Influenza, Hepatitis B, Japanese Encephalitis, Malaria, Ebola, Tuberculosis, Anthrax, HIV, RSV, Zika, Typhoid Fever, Shigella, and Opioid Addiction vaccines. The company operates from Adelaide, South Australia, and has delivered 8 million doses of its COVID-19 vaccine in the Middle East through its partner Cinnagen Corporation.

Differentiator

Problem solved

Functional benefit

Brands

• Advax™ Adjuvant Platform: Patented delta inulin polysaccharide adjuvant platform used in Vaxine's vaccine formulations.
• Covax-19/SpikoGen®
• ADVAX-CPG Adjuvant

Products and services

• Advax-Adjuvanted COVID-19 Vaccine A COVID-19 vaccine formulated with Vaxine's proprietary Advax adjuvant, designed to enhance immunogenicity and enable dose-sparing. Developed for and supplied to government health authorities following TGA regulatory approval in Australia.
• Advax Adjuvant Platform

Quantifiable outcome

• Phase 3 trial with 16,876 participants demonstrated 78% protection against severe disease caused by Delta variant
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Cinnagen CorporationcoreChannel Partner/ Reseller/ DistributorCinnagen Corporation serves as the distribution partner for Vaxine's COVID-19 vaccine (SpikoGen/Covax-19) in the Middle East. They have delivered 8 million doses of the vaccine. Cinnagen also conducted Phase 3 clinical trials of Vaxine's COVID-19 vaccine technology, with Phase 2 results announced in July 2021.
• Matrivax InccoreStrategic or Co-development PartnerCollaboration with Boston-based Matrivax Inc to develop a typhoid fever vaccine using Vaxine's Advax adjuvant platform. The goal is to provide stronger and longer lasting protection extending for at least 10 years.
• Protein SciencesminorStrategic or Co-development PartnerCollaboration with Protein Sciences to develop a Zika vaccine based on a recombinant Zika protein plus Vaxine's Advax adjuvant platform. The vaccine has shown high levels of neutralizing antibodies in animal models.
• Institute for Molecular MedicinecoreStrategic or Co-development PartnerCollaboration on Alzheimer's disease vaccine development. The vaccine aims to stimulate the immune system to produce antibodies that target pathological molecules associated with Alzheimer's disease.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• GSK (Vaccines): World's largest vaccine company by revenue with AS01/AS03 adjuvant platforms (e.g., Shingrix, Cervarix). Peer on vaccine-adjuvant technology and global regulatory/distribution capabilities, though much broader scope than Vaxine.
• Sanofi Pasteur: Global vaccine leader with broad infectious disease portfolio including Fluzone, hepatitis B, and pandemic preparedness products. Comparable as an established vaccine company with multiple adjuvanted formulations and government distribution channels that Vaxine could license into.
• Seqirus (CSL Seqirus): Major influenza and pandemic vaccine producer (part of CSL), Australia-based like Vaxine. Adjacent rather than head-to-head because Seqirus focuses on cell-based and egg-based flu vaccines at industrial scale, but competes for the same government and pandemic preparedness RFPs.

Regional players

• Bio Farma: Indonesia's state-owned vaccine manufacturer producing EPI vaccines, hepatitis B, and pandemic vaccines for regional distribution. Similar focus on adjuvant-enhanced infectious disease vaccines for emerging-market government buyers.

Emerging players

• MigVax: Israeli oral COVID-19 vaccine spin-out focused on mucosal/therapeutic vaccines. Comparable as an early-stage biotech leveraging novel vaccine modalities against viral diseases, operating with similar headcount-scale and capital-intensity profile.
• Matrivax Inc: Boston-based vaccine biotech developing a Typhoid Vi polysaccharide vaccine using Vaxine's Advax adjuvant. An existing partner and therefore a strong comparable on the licensing/adjuvant business model.
• Bavarian Nordic: Specialty vaccine company focused on smallpox/monkeypox (JYNNEOS) and rabies, with growing infectious disease pipeline. Comparable scale and product-platform focus, with growing commercial footprint in Western markets.

Direct peers

• Dynavax Technologies: US biotech that commercialized the CpG 1018 adjuvant used in HEPLISAV-B hepatitis B vaccine. Adjuvant-platform specialist with comparable adjuvant-vaccine business model and licensing DNA.
• Novavax: US biotech developing recombinant protein nanoparticle vaccines (including its own COVID-19 vaccine, Nuvaxovid) using a proprietary Matrix-M adjuvant. Closest direct peer to Vaxine in recombinant spike protein COVID vaccines adjuvanted with proprietary adjuvant platforms.
• Bharat Biotech: Indian vaccine manufacturer with broad infectious disease pipeline (Covaxin for COVID-19, Rotavac, Typbar) that operates across emerging markets and partners for global distribution — closely comparable to Vaxine's adjuvant-platform model targeting infectious diseases in Asia/Middle East.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/vaxine_news

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaxine